A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy
双互补位 HER2 靶向抗体-药物偶联物可诱导对 HER2 靶向治疗有耐药性或不适合 HER2 靶向治疗的原发性模型中的肿瘤消退
期刊:Cancer Cell
影响因子:48.8
doi:10.1016/j.ccell.2015.12.008
John Y Li, Samuel R Perry, Vanessa Muniz-Medina, Xinzhong Wang, Leslie K Wetzel, Marlon C Rebelatto, Mary Jane Masson Hinrichs, Binyam Z Bezabeh, Ryan L Fleming, Nazzareno Dimasi, Hui Feng, Dorin Toader, Andy Q Yuan, Lan Xu, Jia Lin, Changshou Gao, Herren Wu, Rakesh Dixit, Jane K Osbourn, Steven R C
